Use of hematopoietic colony-stimulating factors: The American Society of Clinical Oncology survey

Journal of Clinical Oncology

Volumn 14, Issue 9, 1996, Pages 2511-2520

  Bennett, C L ^a   Smith, T J ^a   Weeks, J C ^a   Bredt, A B ^a   Feinglass, J ^a   Fetting, J H ^a   Hillner, B E ^a   Somerfield, M R ^a   Winn, R J ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CLINICAL PRACTICE; DRUG APPROVAL; HEALTH SURVEY; HUMAN; IMMUNOPROPHYLAXIS; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0029764366     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.9.2511     Document Type: Article

References (7)

1. Vose JM, Annitagc JO: Clinical applications of hematopoietic growth factors. J Clin Oncol 13:1023-1035, 1995
2. Lyman GH, Lyman CG, Sanderson RA, et al: Decision analysis of hematopoeitic growth factors in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493, 1993
3. American Society of Clinical Oncology: Recommendations for the use of hematopoietic growth factors: Evidence based clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
4. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 16:297-334, 1951
5. Amgen Inc: Neupogen (filgrastim). Package insert. Thousand Oaks, CA, Amgen, 1991
6. Immunex Corporation: Leukine (sargramostim). Package insert. Seattle, WA, Immunex, 1991
7. Wennberg J, Gittelsohn A: Small area variations in health care delivery. Science 182:1102-1108, 1973